Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $52,265.20 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Day One Biopharmaceuticals Stock Up 1.6 %

Shares of NASDAQ DAWN opened at $12.43 on Friday. The stock’s fifty day simple moving average is $12.37 and its 200 day simple moving average is $13.47. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. Day One Biopharmaceuticals, Inc. has a 52-week low of $11.13 and a 52-week high of $18.07.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of DAWN. FMR LLC lifted its stake in Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock valued at $163,284,000 after buying an additional 5,475,087 shares in the last quarter. Braidwell LP raised its holdings in shares of Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after acquiring an additional 1,837,949 shares during the period. Franklin Resources Inc. raised its holdings in shares of Day One Biopharmaceuticals by 0.3% during the fourth quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company’s stock valued at $49,197,000 after acquiring an additional 13,320 shares during the period. Estuary Capital Management LP lifted its position in shares of Day One Biopharmaceuticals by 35.5% in the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock valued at $47,092,000 after acquiring an additional 972,997 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in Day One Biopharmaceuticals by 17.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company’s stock worth $44,219,000 after purchasing an additional 507,398 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analyst Ratings Changes

DAWN has been the subject of a number of recent analyst reports. Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, February 10th. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.